Bluebird Bio Ownership
| BLUE Stock | USD 0.49 0.01 2.08% |
Shares in Circulation | First Issued 2012-09-30 | Previous Quarter 193 M | Current Value 194 M | Avarage Shares Outstanding 57.8 M | Quarterly Volatility 39.2 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Bluebird |
Bluebird Stock Ownership Analysis
About 44.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.8. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bluebird bio has Price/Earnings To Growth (PEG) ratio of 0.32. The entity recorded a loss per share of 2.3. The firm had not issued any dividends in recent years. Bluebird Bio had 1544:1000 split on the 5th of November 2021. bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts. Bluebird Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 518 people. For more info on Bluebird bio please contact Andrew Obenshain at 339 499 9300 or go to https://www.bluebirdbio.com.Besides selling stocks to institutional investors, Bluebird Bio also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Bluebird Bio's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Bluebird Bio's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Bluebird Bio Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of Bluebird bio are currently held by insiders. Unlike Bluebird Bio's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Bluebird Bio's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Bluebird Bio's insider trades
Bluebird Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bluebird Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bluebird bio backward and forwards among themselves. Bluebird Bio's institutional investor refers to the entity that pools money to purchase Bluebird Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Deutsche Bank Ag | 2024-06-30 | 1.2 M | Jane Street Group Llc | 2024-06-30 | 1.1 M | Bleichroeder Lp | 2024-06-30 | 1 M | Masters Capital Management Llc | 2024-06-30 | 975 K | Woodline Partners Lp | 2024-06-30 | 969.3 K | Two Sigma Investments Llc | 2024-06-30 | 908 K | Susquehanna International Group, Llp | 2024-06-30 | 901.9 K | Two Sigma Advisers, Llc | 2024-06-30 | 846.2 K | Renaissance Technologies Corp | 2024-06-30 | 791.5 K | Blackrock Inc | 2024-06-30 | 15.4 M | Vanguard Group Inc | 2024-06-30 | 10.3 M |
Bluebird bio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bluebird Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bluebird Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bluebird Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Colvin Richard A over three months ago Disposition of 2343 shares by Colvin Richard A of Bluebird Bio at 2.9769 subject to Rule 16b-3 | ||
Sterling O. James over three months ago Acquisition by Sterling O. James of 300000 shares of Bluebird Bio at 0.98 subject to Rule 16b-3 | ||
Cloonan Michael over three months ago Insider Trading | ||
Jeffrey Walsh over six months ago Sale by Jeffrey Walsh of 300 shares of Bluebird Bio | ||
Jeffrey Walsh over six months ago Exercise or conversion by Jeffrey Walsh of 100 shares of Bluebird Bio subject to Rule 16b-3 | ||
Jeffrey Walsh over a year ago Sale by Jeffrey Walsh of 200 shares of Bluebird Bio | ||
Jeffrey Walsh over a year ago Sale by Jeffrey Walsh of 100 shares of Bluebird Bio |
Bluebird Bio Outstanding Bonds
Bluebird Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bluebird bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bluebird bonds can be classified according to their maturity, which is the date when Bluebird bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| F | Ford Motor | |
| CRM | Salesforce |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bluebird bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.30) | Revenue Per Share 0.357 | Quarterly Revenue Growth 1.337 | Return On Assets (0.36) | Return On Equity (1.87) |
The market value of Bluebird bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bluebird Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bluebird Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.